Get the Stockscreener App
83.49
2.04%
1.6601
Illumina Inc stock is traded at $83.49, with a volume of 564.46K.
It is up +2.04% in the last 24 hours and up +7.22% over the past month.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
See More
Previous Close:
$81.83
Open:
$82.24
24h Volume:
564.46K
Relative Volume:
0.25
Market Cap:
$13.23B
Revenue:
$4.34B
Net Income/Loss:
$-965.00M
P/E Ratio:
-13.75
EPS:
-6.07
Net Cash Flow:
$869.00M
1W Performance:
-1.10%
1M Performance:
+7.22%
6M Performance:
-41.40%
1Y Performance:
-18.19%
1-Day Range:
$82.07
$83.91
1-Week Range:
$78.79
$85.90
52-Week Range:
$68.70
$156.66
Illumina Inc Stock (ILMN) Company Profile
Name
Illumina Inc
Sector
Industry
Phone
(858) 202-4500
Address
5200 ILLUMINA WAY, SAN DIEGO, CA
Compare ILMN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ILMN
Illumina Inc
|
83.55 | 13.06B | 4.34B | -965.00M | 869.00M | -6.07 |
|
TMO
Thermo Fisher Scientific Inc
|
405.00 | 152.34B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
194.26 | 135.39B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
527.49 | 41.54B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
114.95 | 31.61B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
148.51 | 24.31B | 15.50B | 1.33B | 2.16B | 7.34 |
Illumina Inc Stock (ILMN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-04-25 | Reiterated | Citigroup | Neutral |
| Feb-28-25 | Downgrade | HSBC Securities | Buy → Hold |
| Feb-10-25 | Downgrade | Barclays | Equal Weight → Underweight |
| Feb-07-25 | Downgrade | TD Cowen | Buy → Hold |
| Dec-11-24 | Downgrade | Citigroup | Buy → Neutral |
| Nov-12-24 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-17-24 | Upgrade | HSBC Securities | Hold → Buy |
| Aug-28-24 | Upgrade | Argus | Hold → Buy |
| Aug-16-24 | Upgrade | Daiwa Securities | Neutral → Buy |
| Aug-14-24 | Upgrade | Barclays | Underweight → Equal Weight |
| Aug-14-24 | Upgrade | TD Cowen | Hold → Buy |
| Jul-10-24 | Upgrade | Citigroup | Neutral → Buy |
| Jun-03-24 | Resumed | Jefferies | Hold |
| Jan-16-24 | Downgrade | HSBC Securities | Buy → Hold |
| Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Dec-18-23 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| Dec-15-23 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-14-23 | Initiated | Stephens | Overweight |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Dec-12-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-11-23 | Upgrade | Citigroup | Sell → Neutral |
| Nov-10-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Sep-28-23 | Initiated | Bernstein | Underperform |
| Jul-05-23 | Resumed | JP Morgan | Neutral |
| Jan-25-23 | Downgrade | Argus | Buy → Hold |
| Jan-05-23 | Initiated | Scotiabank | Sector Perform |
| Dec-12-22 | Downgrade | Citigroup | Neutral → Sell |
| Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
| Oct-04-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-28-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-25-22 | Initiated | Credit Suisse | Neutral |
| Jul-13-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Jan-18-22 | Upgrade | Stifel | Hold → Buy |
| Jan-11-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Jan-07-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Aug-19-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jun-01-21 | Upgrade | Evercore ISI | Underperform → In-line |
| Mar-31-21 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Mar-31-21 | Upgrade | Canaccord Genuity | Hold → Buy |
| Mar-03-21 | Initiated | Barclays | Underweight |
| Dec-22-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-17-20 | Upgrade | BTIG Research | Neutral → Buy |
| Oct-13-20 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-30-20 | Initiated | Atlantic Equities | Overweight |
| Sep-29-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-22-20 | Downgrade | Stifel | Buy → Hold |
| Sep-22-20 | Downgrade | UBS | Buy → Neutral |
| Sep-21-20 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-21-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Aug-07-20 | Downgrade | Evercore ISI | In-line → Underperform |
| Aug-07-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-07-20 | Downgrade | Guggenheim | Buy → Neutral |
| Apr-24-20 | Downgrade | Citigroup | Buy → Neutral |
| Apr-21-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jan-08-20 | Initiated | Wells Fargo | Underweight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-15-19 | Initiated | Stifel | Buy |
| Oct-25-19 | Initiated | Guggenheim | Buy |
View All
Illumina Inc Stock (ILMN) Latest News
Microbiome Sequencing Market Outlook 2025-2029 | Affordable Sequencing Instruments Expand Market Access for Smaller Labs - Yahoo
Forensic Genomics Market Research 2025Global Trends, Opportunity, and Forecasts 2020-2030 - GlobeNewswire Inc.
Digital Genome Market Deep Research Report on AI-Driven DNA Analysis Trends | Illumina, Thermo Fisher Scientific - openPR.com
Cancer Profiling Market Is Booming So Rapidly 2025-2032 - openPR.com
Hereditary Testing MarketGlobal Industry Trends, Opportunity, and Forecast, 2020-2030: Key Players Like Illumina and Myriad Genetics Leading the Charge - Yahoo
Next-Gen RNA Sequencing Market | Personalized Medicine & Future - openPR.com
Gene Panel Market Projected to Witness Massive GrowthIllumina, Inc., Thermo Fisher Scientific - openPR.com
Illumina Connected Insights - Technology Networks
Illumina Inc (ILMN) Stock Price Down 3.31% on May 30 - GuruFocus
Genotyping Assay Market Deep Research Report Highlights Key AdvancementsIllumina, Thermo Fisher Scientific - openPR.com
Illumina’s PromoterAI unlocks rare disease clues in noncoding genome - statnews.com
Illumina Introduces a New AI algorithm PromoterAI: Stock to Gain? - Yahoo Finance
Epigenetics Market Analysis 2025-2033: Advances in DNA - openPR.com
Illumina introduces PromoterAI for rare disease diagnosis By Investing.com - Investing.com South Africa
Illumina Inc.: Tackling Global Headwinds With Strategic Market Diversification! - Smartkarma
Illumina, Inc. (ILMN) Unveils AI Breakthrough for Rare Disease Diagnosis - Insider Monkey
Illumina introduces PromoterAI for rare disease diagnosis - Investing.com Australia
Operating a speedy, high-tech NGS lab in remote Australia - Illumina
Illumina unveils PromoterAI, a groundbreaking algorithm to accelerate insights for rare disease diagnosis - PR Newswire
Bioinformatics Market Detailed in New Research ReportThermo Fisher Scientific, Illumina - openPR.com
DNA giant Illumina spawned an ecosystem of competitors and customers - Endpoints News
Illumina widens access to cancer tests with Medicare and new CDx - Yahoo Finance
Patent Fight Breaks Out over Genetic Sequencing - Orthopedics This Week
Illumina at Bernstein Conference: Strategic Insights and Challenges - Investing.com
Transcript : Illumina, Inc. Presents at Bernstein 41st Annual Strategic Decisions Conference 2025, May-28-2025 02 - marketscreener.com
Stifel Affirms Buy Rating on Illumina (ILMN) Stock - MSN
Illumina Expands Clinical Oncology Portfolio Unlocking New Standard of Care and Access to Precision Therapies - marketscreener.com
Illumina Expands Clinical Oncology Portfolio Unlocking New Standard Of Care And Access To Precision Therapies - marketscreener.com
Gene Expression Software Market Growth Projected at CAGR of 7.8% - openPR.com
Lab-on-a-chip and Microarrays (Biochip) Market Generated - openPR.com
Illumina expands oncology portfolio with new FDA-approved test By Investing.com - Investing.com Canada
Illumina expands oncology portfolio with new FDA-approved test - Investing.com
Illumina expands clinical oncology portfolio unlocking new standard of care and access to precision therapies - PR Newswire
Stifel maintains Illumina stock buy rating, $135 target - Investing.com
Illumina's TSO Comprehensive Earns Japan's Approval: Stock to Gain? - Yahoo Finance
Illumina at ESHG 2025 - Illumina
Video: How researchers are moving multiomics forward with Illumina technology - Illumina
GC Genome plans $30M IPO to diversify genomic products, suppliers - BioWorld MedTech
Microfluidic Market Is Booming Worldwide | Agilent Technologies, Inc., Illumina, Inc., Perkinelmer, Inc. - openPR.com
DNA Forensic Solution Market Size, Share & Trend, Regional - openPR.com
Single Cell Genome Sequencing Market to Witness Massive Growth - openPR.com
Illumina’s SWOT analysis: genetic giant’s stock faces China headwinds By Investing.com - Investing.com Nigeria
Illumina’s SWOT analysis: genetic giant’s stock faces China headwinds - Investing.com
Cell-Free DNA Isolation and Extraction Market - GlobeNewswire Inc.
Cathie Wood Reiterates 'Profound' AI Application In Healthcare As Researchers Discover 'Cancer Survival Outcomes' By Facial Photograph Analysis: Here Are The Stocks That Could BenefitInvesco QQQ Trust, Series 1 (NASDAQ:QQQ), Illumina (NASDAQ:IL - Benzinga
Life Sciences Tools & Services Stocks Q1 Recap: Benchmarking Illumina (NASDAQ:ILMN) - Yahoo Finance
Tumor Profiling Market May Set New Growth Story | Illumina Inc., - openPR.com
Illumina Approves Key Proposals at Annual Meeting - TipRanks
Genotyping Market to Reach $61.6 Billion, Globally, by 2033 - openPR.com
Customized CRISPR for KJ, 10x and Illumina Lawsuits, Regeneron Bags 23andMe - Genetic Engineering and Biotechnology News
Illumina Stock to Gain From the Launch of New DRAGEN v4.4 Software - MSN
Illumina Inc Stock (ILMN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.83%
0.34%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):